In a significant leap forward, the Food and Drug Administration (FDA) is moving closer to approving the first therapy utilizing CRISPR gene-editing technology. The potential approval of Exa-cel, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, marks a milestone in the treatment of hereditary disorders such as sickle cell disease.

Why it Matters: Directly editing genes within a patient’s body could be a life-altering breakthrough for individuals grappling with debilitating hereditary conditions, particularly sickle cell disease. This innovative therapy focuses on addressing the root causes of the disease.

The Exa-cel Therapy: Exa-cel, designed for patients aged 12 and above, offers a one-time treatment approach. The therapy involves editing a patient’s stem cells to produce elevated levels of fetal hemoglobin. This specific approach aims to counteract the impact of defective hemoglobin prevalent in individuals with sickle cell disease.

Alcohol addiction, a pervasive and destructive force in countless lives, may soon face a groundbreaking solution as scientists make remarkable progress in their quest to combat this enduring problem.

The Promising Trials on Primates:

In a significant step forward in the field of addiction treatment, experimental therapy for alcohol use disorder (AUD) has entered the trial phase in monkeys, yielding impressive results. If these findings can be replicated in humans, it could mark a turning point in the battle against AUD.

Renowned neuroscientists and physiologists from various institutes across the US have dedicated years to understanding the intricate nature of addiction. They have tested a pioneering gene therapy designed to engage and modify the core brain circuitry responsible for prolonged heavy alcohol consumption. One of the major challenges in treating AUD is the issue of relapse. Despite determined efforts to abstain, many individuals find themselves inexorably drawn back to alcohol.